Xbrane Biopharma AB (publ) (STO:XBRANE)

Market Cap	364.05M
Revenue (ttm)	277.89M
Net Income (ttm)	-160.65M
Shares Out	1.53B
EPS (ttm)	-0.11
PE Ratio	n/a
Forward PE	1.11
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,804,120
Average Volume	21,751,501
Open	0.2510
Previous Close	0.2504
Day's Range	0.2250 - 0.2646
52-Week Range	0.1262 - 0.3580
Beta	0.83
RSI	53.78
Earnings Date	May 8, 2025

About Xbrane Biopharma AB

Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn’s disease and axial s...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 65
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: XBRANE

Financial Performance

In 2024, Xbrane Biopharma AB's revenue was 198.72 million, a decrease of -16.76% compared to the previous year's 238.73 million. Losses were -266.22 million, -31.42% less than in 2023.